Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Minnesota Oncology - Minneapolis

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

  • Details

ClinicalTrials.gov ID: NCT05885698
Diagnosis Type: Lung Cancer
USOR Number: 22285

  • Practice Details

910 E 26th St, Suite 200
Minneapolis, MN 55404
P: (612) 884-6300

More Details View Practice Page

Lung Cancer

Clinical Trial at: Minnesota Oncology - Edina

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

  • Details

ClinicalTrials.gov ID: NCT05885698
Diagnosis Type: Lung Cancer
USOR Number: 22285

  • Practice Details

6545 France Avenue, Suite 210
Edina, MN 55435
P: (952) 928-2900

More Details View Practice Page

Lung Cancer

Clinical Trial at: Minnesota Oncology - Fridley

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

  • Details

ClinicalTrials.gov ID: NCT05885698
Diagnosis Type: Lung Cancer
USOR Number: 22285

  • Practice Details

480 Osborne Rd NE, Suite 220
Fridley, MN 55432
P: (763) 786-1620

More Details View Practice Page

Lung Cancer

Clinical Trial at: Minnesota Oncology - Coon Rapids

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

  • Details

ClinicalTrials.gov ID: NCT05885698
Diagnosis Type: Lung Cancer
USOR Number: 22285

  • Practice Details

11850 Blackfoot St NW, Suite 100
Coon Rapids, MN 55433
P: (763) 712-2100

More Details View Practice Page

Lung Cancer

Clinical Trial at: Minnesota Oncology - Burnsville

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

  • Details

ClinicalTrials.gov ID: NCT05885698
Diagnosis Type: Lung Cancer
USOR Number: 22285

  • Practice Details

675 E Nicollet Blvd, Suite 100
Burnsville, MN 55337
P: (952) 892-7190

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Minnesota Oncology - Woodbury

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

6025 Lake Rd, Suite 110
Woodbury, MN 55125
P: (651) 735-7414

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Minnesota Oncology - Edina

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

6545 France Avenue, Suite 210
Edina, MN 55435
P: (952) 928-2900

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Minnesota Oncology - Maplewood

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

1580 Beam Avenue
Maplewood, MN 55109
P: (651) 779-7978

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Minnesota Oncology - Minneapolis

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

910 E 26th St, Suite 200
Minneapolis, MN 55404
P: (612) 884-6300

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Minnesota Oncology - Coon Rapids

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

11850 Blackfoot St NW, Suite 100
Coon Rapids, MN 55433
P: (763) 712-2100

More Details View Practice Page
1 2 3 4 … 14

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.